Interestingly, CCL3 treatment lowered serum IgG1 in diabetic mice to levels similar to those of nondiabetic controls (Figure 3), suggesting a beneficial CCL3-induced modulation of dysregulated adaptive immune responses that are commonly associated with diabetes [38,39,44]. Here, CCL3 is linked to diabetes mellitus.